Joseph Zakrzewski, executive chairman, Amarin

pharmafile | January 13, 2010 | Appointment | Research and Development Amarin, appointment, research and development 

Dublin-headquartered biotech Amarin has appointed Joseph Zakrzewski executive chairman.

He is currently the chief executive of Xcellerex, a Massachusetts-based biotechnology company, and serves on the board of directors of Insulet Corporation and is chairman of the boards of directors for Promedior and Zelos Therapeutics.

Zakrzewski has more than 20 years of industry experience, including making significant contributions to Reliant Pharmaceuticals as chief operating officer in the lead up to its 2007 acquisition by GlaxoSmithKline.

He has also spent 17 years at Lilly in a variety of roles, including VP of corporate business development where he had global responsibility for licensing activities.

Advertisement

Commenting on his appointment Zakrzewski said: “Having reviewed Amarin’s compelling business plan and cardiovascular development strategy, I am pleased to be joining the company’s board of directors as executive chairman.

“With AMR101 poised to enter phase III clinical trials, and the combination of the company’s recent financing by top-tier investors, the composition of its board and the high quality management team, I believe this is a unique opportunity to create value for Amarin shareholders.”

Previous chairman Thomas Lynch will continue to serve as a member of Amarin’s board of directors.

Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months

TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …

The Gateway to Local Adoption Series

Latest content